Inhibitors | Comment | Organism | Structure |
---|---|---|---|
1,10-phenanthroline | - |
Homo sapiens | |
2,2'-Dithiopyridine | strong | Homo sapiens | |
Acetyl-Val-Leu-Leu-Arg-Ala-Ser-Val-Ala | weak | Homo sapiens | |
Cu2+ | strong | Homo sapiens | |
Diazoacetyl norleucine methyl ester | weak | Homo sapiens | |
diisopropyl fluorophosphate | strong, Val-Leu-Leu-Arg-Ala-Ser-Val-Ala protects | Homo sapiens | |
Hg2+ | strong, reversible by dialysis against 2 mM DTT | Homo sapiens | |
IAA | - |
Homo sapiens | |
iodoacetate | - |
Homo sapiens | |
additional information | no inhibition by Val-Leu-Arg, isovaleryl-Val-Leu-Arg-Arg-Ala-Ser-Val-Ala, EDTA (with or without DTT) | Homo sapiens | |
NEM | strong | Homo sapiens | |
PCMB | - |
Homo sapiens | |
pepstatin | weak | Homo sapiens | |
PMSF | strong, irreversible, Val-Leu-Leu-Arg-Ala-Ser-Val-Ala protects | Homo sapiens | |
Soybean trypsin inhibitor | weak | Homo sapiens | |
trans-epoxysuccinyl-L-leucinamido(4-guanidino)butane | i.e. E-64, weak | Homo sapiens |
KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|
0.013 | - |
Arg-Arg-Ala-(phospho)Ser-Val-Ala | - |
Homo sapiens | |
0.016 | - |
Ala-Ala-Phe 4-methylcoumarin 7-amide | - |
Homo sapiens |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
cytosol | - |
Homo sapiens | 5829 | - |
cytosol | - |
Rattus norvegicus | 5829 | - |
Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
---|---|---|---|
135000 | - |
x * 135000, SDS-PAGE under reducing conditions | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Rattus norvegicus | - |
- |
- |
Purification (Comment) | Organism |
---|---|
- |
Homo sapiens |
- |
Rattus norvegicus |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
blood | - |
Rattus norvegicus | - |
erythrocyte | - |
Homo sapiens | - |
heart | - |
Rattus norvegicus | - |
kidney | - |
Rattus norvegicus | - |
liver | - |
Homo sapiens | - |
liver | - |
Rattus norvegicus | - |
additional information | tissue distribution | Rattus norvegicus | - |
skeletal muscle | - |
Rattus norvegicus | - |
spleen | - |
Rattus norvegicus | - |
Specific Activity Minimum [µmol/min/mg] | Specific Activity Maximum [µmol/min/mg] | Comment | Organism |
---|---|---|---|
4.245 | - |
- |
Homo sapiens |
5.4 | - |
- |
Rattus norvegicus |
Storage Stability | Organism |
---|---|
-70°C, frozen in liquid nitrogen, stable | Homo sapiens |
-70°C, frozen in liquid nitrogen, stable | Rattus norvegicus |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
Ala-Ala-Phe 2-naphthylamide + H2O | at 41% the rate of Ala-Ala-Phe 7-amido-4-methylcoumarin | Homo sapiens | Ala-Ala-Phe + 2-naphthylamine | - |
? | |
Ala-Ala-Phe 7-amido-4-methylcoumarin + H2O | - |
Rattus norvegicus | Ala-Ala-Phe + 7-amino-4-methylcoumarin | - |
? | |
Ala-Ala-Phe 7-amido-4-methylcoumarin + H2O | best chromogenic tripeptyl substrate | Homo sapiens | Ala-Ala-Phe + 7-amino-4-methylcoumarin | - |
? | |
Arg-Ala-Ser-Val-Ala + H2O | - |
Homo sapiens | Arg-Ala-Ser + Val-Ala | - |
? | |
Arg-Arg-Ala-(phospho)Ser-Val-Ala + H2O | - |
Homo sapiens | Arg-Arg-Ala + (phospho)Ser-Val-Ala | - |
? | |
Arg-Arg-Ala-(phospho)Ser-Val-Ala + H2O | - |
Rattus norvegicus | Arg-Arg-Ala + (phospho)Ser-Val-Ala | - |
? | |
Arg-Arg-Ala-Ser-Val + H2O | - |
Rattus norvegicus | Arg-Arg-Ala + Ser-Val | - |
? | |
His-Leu-His 2-naphthylamide + H2O | at 12% the rate of Ala-Ala-Phe 4-methylcoumarin 7-amide | Homo sapiens | His-Leu-His + 2-naphthylamine | - |
? | |
additional information | no substrate: Arg-Arg-Pro-Ser-Val | Rattus norvegicus | ? | - |
? | |
additional information | no substrate: Pro-Lys-Ala 2-naphthylamide | Homo sapiens | ? | - |
? | |
Phe-Pro-Ala 2-naphthylamide + H2O | at 6% the rate of Ala-Ala-Phe 4-methylcoumarin 7-amide | Homo sapiens | Phe-Pro-Ala + 2-naphthylamine | - |
? | |
Val-Gly-Ala-His-Ala-Gly-Glu-Tyr-Gly-Ala-Glu-Ala-Leu-Glu-Arg + H2O | peptide derived from human hemoglobin alpha-chain, residues 17-31, sequential release of tripeptides from free N-terminus, cleaved into 5 tripeptides by human enzyme, cleavage of Gly25-Ala bond occurs at a lower rate than Ala19-His and Gly22-Glu | Homo sapiens | Val-Gly-Ala + His-Ala-Gly + Glu-Tyr-Gly + Ala-Glu-Ala + Leu-Glu-Arg | - |
? | |
Val-Leu-Arg-Arg-Ala-Ser-Val-Ala + H2O | - |
Homo sapiens | Val-Leu-Arg + Arg-Ala-Ser-Val-Ala | the latter product is cleaved at a higher rate than the substrate | ? | |
Val-Tyr-Ser 2-naphthylamide + H2O | at 3% the rate of Ala-Ala-Phe 4-methylcoumarin 7-amide | Homo sapiens | Val-Tyr-Ser + 2-naphthylamine | - |
? |
Subunits | Comment | Organism |
---|---|---|
? | - |
Rattus norvegicus |
? | x * 135000, SDS-PAGE under reducing conditions | Homo sapiens |
pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|
7.5 | - |
hydrolysis of Ala-Ala-Phe 4-methylcoumarin 7-amide | Homo sapiens |
7.5 | - |
hydrolysis of Arg-Arg-Ala-(phospho)Ser-Val-Ala | Homo sapiens |
7.5 | - |
hydrolysis of Arg-Arg-Ala-(phospho)Ser-Val-Ala | Rattus norvegicus |